Sign In
Buy INM
$1.57
-0.0700 (-4.27%)
At Close: Jul 13, 2026
Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders?
07:15pm, Monday, 06'th Jul 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered in
Are GBTG, INM, CZR, TMHC Obtaining Fair Deals for their Shareholders?
11:51am, Friday, 12'th Jun 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
05:00pm, Thursday, 04'th Jun 2026
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing
Are RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders?
06:57pm, Thursday, 28'th May 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RAMP, NEE, D, and INM
03:00pm, Thursday, 28'th May 2026
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RAMP, NEE, D, and INM PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—D, INM, ESQ, and GDOT
10:48am, Wednesday, 27'th May 2026
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
InMed Pharmaceuticals Inc. (INM) M&A Call Prepared Remarks Transcript
02:37pm, Monday, 25'th May 2026
InMed Pharmaceuticals Inc. (INM) M&A Call Prepared Remarks Transcript
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of InMed Pharmaceuticals, Inc. (NASDAQ: INM)
11:02am, Wednesday, 20'th May 2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders a
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM)
06:26pm, Tuesday, 19'th May 2026
BALA CYNWYD, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of InMed Pharmaceuticals, Inc. (“I
/C O R R E C T I O N -- InMed Pharmaceuticals/
03:00pm, Tuesday, 19'th May 2026
/C O R R E C T I O N -- InMed Pharmaceuticals/ PR Newswire VANCOUVER, BC and SAN FRANCISCO, May 19, 2026
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of InMed Pharmaceuticals, Inc. (NASDAQ: INM) and Mentari Therapeutics, Inc. Upon clos
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of InMed Pharmaceuticals, Inc. (NASDAQ: INM) and Mentari Therapeutics, Inc. Upon closing of the pr
Penny Stock InMed Pharmaceuticals Merger Deal Targets Migraine Pipeline
10:05am, Tuesday, 19'th May 2026
InMed Pharmaceuticals Inc. (NASDAQ:INM) shares are up during Tuesday's premarket session, as the company announced a merger agreement with Mentari Therapeutics.
InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies
08:00am, Tuesday, 19'th May 2026
Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies Concurrent oversubs
